Non-small cell lung cancer
Conditions
Interventions
experimental group:Chemotherapy plus anlotinib
control group:chemotherapy group
Sponsors
He'nan Provincial Chest Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Unresectable stage III (IIIA) lung adenocarcinoma confirmed histologically or cytologically; 2. The eastern cooperative oncology group (ECOG) had a physical state of 0 or 1; 3. No prior chemotherapy, radiation, biotherapy or lung cancer surgery; 4. And has normal organ and bone marrow hematopoietic function. 5. Classification of tumors according to joint committee 8 of the American cancer staging system. N2 was defined as mediastinal lymph node involvement, with a maximum axial size of > 1 cm. Exclude fused lymph nodes; Multiple site lymph node involvement; Or groups of multiple small positive lymph nodes (> 2 cm).
Exclusion criteria
Exclusion criteria: 1. Scalenus, contralateral supraclavicular or hilar or mediastinal lymph node enlargement or involvement of the vertebral body; 2. Patients with secondary primary malignancy or tumor invasion of great vessels;Allergic history of treatment with other drugs specifically targeting VEGF; 3. History of allergy to other recombinant human antibodies; 4. A history of stroke or transient ischemic attack; 5. history of myocardial infarction or unstable angina in the past 12 months; 6. Other serious diseases or co-existing major diseases, including unstable heart disease requiring treatment, major neurological or psychiatric disorders (including psychosis, dementia or seizures), symptomatic diverticulitis, uncontrolled hypertension, and uncontrolled proteinuria; 6. Poorly controlled or uncontrolled infection of diabetes mellitus; 7. Patients with oblique muscles, contralateral supraclavicular or hilar or mediastinal lymphadenopathy or vertebral involvement 8. Including patients with second primary malignant tumors or tumors that invade large blood vessels; 9. Use other drugs that specifically target VEGF to treat allergies; Pregnant or lactating women.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Excision rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;Overall survival; | — |
Countries
China
Contacts
Public ContactGuolei Wang
He'nan Provincial Chest Hospital
Outcome results
None listed